|
melanoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Inhibitors of RAF inhibit the MAPK pathway that plays an important role in the development and progression of those melanoma carrying the V600E BRAF mutation, but there's a subset of such patients who do not respond to the therapy.
|
24710085 |
2015 |
|
melanoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
RAF inhibitor therapy yields significant reductions in tumour burden in the majority of V600E-positive melanoma patients; however, resistance occurs within 2-18 months.
|
24849047 |
2014 |
|
melanoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Patients with mutant BRAF melanoma that progress on RAF inhibitors have limited treatment options, and drug removal from resistant tumors may elicit multiple effects.
|
24520098 |
2014 |
|
melanoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
We conclude that loss of NF1 is common in cutaneous melanoma and is associated with RAS activation, MEK-dependence, and resistance to RAF inhibition.
|
24576830 |
2014 |
|
melanoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
We sought to preemptively determine mutations in ERK1/2 that confer resistance to either ERK inhibitors or combined RAF/MEK inhibition in BRAF(V600)-mutant melanoma.
|
25320010 |
2014 |
|
melanoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Next, in a melanoma model, we screened for genes whose loss is involved in resistance to vemurafenib, a therapeutic RAF inhibitor.
|
24336571 |
2014 |
|
melanoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
In conclusion, we report that (WT)BRAF/(WT)NRAS melanoma lines with low phospho-CRAF and high cAMP levels may be sensitive to vemurafenib and that CRAF inhibition through cAMP stimulation may overcome the resistance to the drug.
|
24559688 |
2014 |
|
melanoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
RAF is among the most frequently mutated kinases, where BRAF V600E mutation occurs in most hairy cell leukemias (HCL) and half of malignant melanomas.
|
25034364 |
2014 |
|
melanoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Our results suggest RAC1 P29S status may offer a predictive biomarker for RAF inhibitor resistance in melanoma patients, where it should be evaluated clinically.
|
25056119 |
2014 |
|
melanoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
The pro-apoptotic effects of L-779,450 may explain the antitumor effects of RAF inhibition and may be considered when evaluating RAF inhibitors for melanoma therapy.
|
23955071 |
2014 |
|
melanoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
ATP-competitive RAF inhibitors elicit profound but often temporary antitumor responses in patients with BRAF-mutant melanoma.
|
24402945 |
2014 |
|
melanoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Recent advances in melanoma biology have revealed that RAS-RAF-MEK-ERK signaling has a pivotal role in governing disease progression and treatment resistance.
|
23624923 |
2014 |
|
melanoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond.
|
24957944 |
2014 |
|
melanoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Although most BRAF(V600)-mutant melanomas are sensitive to RAF and/or MEK inhibitors, a subset fails to respond to such treatment.
|
24771846 |
2014 |
|
melanoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Detailed mutational profiling confirmed RAS/RAF screening and identified additional aberrations (NRAS/non-BRAF melanomas; PIK3CA/KRAS colorectal cancer) without therapeutic implications.
|
24947927 |
2014 |
|
melanoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Combination of RAF and MEK inhibition for the treatment of BRAF-mutated melanoma: feedback is not encouraged.
|
25517746 |
2014 |
|
melanoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Evaluation of stromal HGF immunoreactivity as a biomarker for melanoma response to RAF inhibitors.
|
24434899 |
2014 |
|
melanoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Raf-1 kinase inhibitor protein (RKIP) expression was associated with the onset, development, invasion, and metastasis of numerous tumor types including prostate cancer, melanoma, colorectal cancer, liver cancer, and breast cancer.
|
24420151 |
2014 |
|
melanoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
MicroRNA-340 as a modulator of RAS-RAF-MAPK signaling in melanoma.
|
25043973 |
2014 |
|
melanoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Current ATP-competitive RAF inhibitors are active in cancers with somatic RAF mutations, such as BRAF(V600) mutant melanomas.
|
23808890 |
2013 |
|
melanoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
RAF inhibitors such as vemurafenib and dabrafenib block BRAF-mediated cell proliferation and achieve meaningful clinical benefit in the vast majority of patients with BRAF(V600E)-mutant melanoma.
|
23288408 |
2013 |
|
melanoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Melanomas harboring the BRAF V600E mutation have demonstrated sensitivity to both RAF and MAPK/extracellular signal regulated kinase (ERK) inhibitors in vitro and in vivo.
|
24077403 |
2013 |
|
melanoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
To investigate the mechanism(s) of resistance to the RAF-inhibitor vemurafenib, we conducted a comprehensive analysis of the genetic alterations occurring in metastatic lesions from a patient with a BRAF(V600E)-mutant cutaneous melanoma who, after a first response, underwent subsequent rechallenge with this drug.
|
23948972 |
2013 |
|
melanoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
From these, we validated and further characterized novel gene fusions involving ROS1 tyrosine kinase in angiosarcoma (CEP85L/ROS1), SLC1A2 glutamate transporter in colon cancer (APIP/SLC1A2), RAF1 kinase in pancreatic cancer (ATG7/RAF1) and anaplastic astrocytoma (BCL6/RAF1), EWSR1 in melanoma (EWSR1/CREM), CDK6 kinase in T-cell acute lymphoblastic leukemia (FAM133B/CDK6), and CLTC in breast cancer (CLTC/VMP1).
|
23637631 |
2013 |
|
melanoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Activation of the ERK1/2 mitogen-activated protein kinases (MAPK) confers resistance to the RAF inhibitors vemurafenib and dabrafenib in mutant BRAF-driven melanomas.
|
24121492 |
2013 |